NCT06151119Recruiting
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
Source: ClinicalTrials.gov · Last updated 19 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades. To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 21 Nov 2023
- Start date
- 22 Nov 2023
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06151119
What you commit to
- Study type: Observational
- Planned participants: 90
- From 22 Nov 2023 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history);
- Workers who are exposed to radiation for a long period of time;
- Participating in other interventional clinical trials within 1 month before screening;
Other illness
- Known allergic history to 68Ga FAPI or its excipients;
- Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis;
- Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers;
Other
- Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia;
- pregnant and lactating women;
- There are other circumstances that the researcher thinks are not suitable for participating in this study;
Who the study is looking for
- Age ≥18 years old;
- Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
- The expected survival time is over 3 months
- Voluntarily sign informed consent.
- Willing and able to follow the research protocol;
- The subject must be able to lie on the scanning bed for 20 minutes;
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bing Xu Coordinator of this site? Confirm its status | Xiamen | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.